Close
Nordic 9Nordic 9

Zukunftsfonds Heilbronn (investor - Others)

Germany zf-hn.de
See something wrong or missing? Let us know
Offices:Heilbronn

ZFHN - Zukunftsfonds Heilbronn is a privately financed family office from Germany founded in 2005. In 2023 it merged with Born2Grow and changed name into D11Z Ventures.

Average round investment:37.31M USD
Average number per year:1.0
Distribution: 2021 (1)2018 (1)
Portfolio companies: Germany ElevaGermany MetisMotion
Mostly invests in: Germany Germany (2) Biotech (1)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Zukunftsfonds Heilbronn

Name Criteria
Luxembourg Vesalius Biocapital Partners
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United States Obvious Ventures
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Switzerland Essential Investments
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland Roche Venture Fund
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Italy Panakès Partners
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Spain HealthEquity
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Netherlands Thuja Capital Management B.V.
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Netherlands BioGeneration Ventures
76%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Norway Ferd Capital
75%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
Switzerland Novartis Venture Fund
74%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Top